Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102 EUR | +0.69% | +4.51% | +8.11% |
Apr. 22 | GERRESHEIMER AG : Buy rating from Barclays | ZD |
Apr. 22 | GERRESHEIMER AG : Jefferies remains its Buy rating | ZD |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 24.64 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.11% | 3.72B | B+ | ||
-2.25% | 186B | C+ | ||
-1.32% | 107B | C | ||
-3.92% | 67.57B | A | ||
+7.99% | 50.7B | B- | ||
+15.74% | 47.2B | B- | ||
+5.70% | 39.72B | B+ | ||
+10.81% | 27.48B | A- | ||
+2.34% | 25.65B | B | ||
+15.97% | 24.97B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GXI Stock
- Ratings Gerresheimer AG